Pharmaceutical and biotech firms are stepping forward to develop vaccines and treatments that target the infection caused by the coronavirus (Covid-19).
Here are some of the companies CJsGO markets are keeping a close eye on:
Type: Vaccine
Stage: Preclinical
Name: BNT162
Background: On March 17, Pfizer announced that it would help develop and distribute BioNTech SE’s Covid-19 vaccine candidate, though the deal excludes China. BioNTech plans to put the vaccine candidate into clinical trials in late April, in Germany and the U.S. It is testing the vaccine in collaboration with Shanghai Fosun Pharmaceutical Group Co. Ltd. in China. Pfizer and BioNTech for several years have said they would partner to develop mRNA-based influenza vaccines.
YTD Performance: 104%
- Human Papillomavirus Protein E6 Market with top key players: Rottapharm Biotech Srl,Selecta ... on May 30, 2020 at 4:18 am
... key players: Rottapharm Biotech Srl,Selecta Biosciences Inc,Transgene SA,Abion Inc,BioNTech AG,Cancer Research Technology Ltd,Etubics Corp.
- Huge opportunity in Human Papillomavirus Protein E7 Market 2020-2027 with Abion Inc,Advaxis ... on May 30, 2020 at 3:45 am
The key manufacturers covered in this report are: Abion Inc,Advaxis Inc,Bioleaders Corp,BioNTech AG,Cancer Research Technology Ltd,Etubics Corp, ...
Type: Treatment
Stage: Preclinical
Background: Vir said Feb. 25 it is collaborating with Shanghai-based WuXi Biologics to test monoclonal antibodies as a treatment for Covid-19. If the treatment is approved, WuXi will commercialize it in China, while Vir will have marketing rights for the rest of the world. The preclinical company is run by George Scangos, the former CEO of Biogen. It later announced a partnership with Biogen to help develop and manufacture its monoclonal antibodies as a potential treatment for Covid-19. Biogen will handle clinical manufacturing of Vir’s antibodies, the company said.
YTD Performance: Vir 324.9%; Biogen’s 4.9%
- Other news to note for May 29, 2020 on May 29, 2020 at 10:51 pm
Agex Therapeutics Inc., of Alameda, Calif., and Sernova Corp., of London, ... Vir Biotechnology Inc., of San Francisco, said it finalized a process ...
- Court ruling in Keystone XL case is another blow against big US natgas pipes on May 29, 2020 at 4:30 pm
The company was not available for comment on Friday. Dominion ... and Fitch has potential for growth through the year ** Vir Biotechnology Inc VIR.
Type: Treatment
Stage: Phase 3 clinical trials
Name: remdesivir
Background: Gilead is a longtime drugmaker best known for developing the first major cure for hepatitis-C in Sovaldi, a therapy that changed the standard of care for that disease but also kicked off the national debate about drug pricing. The company has experience developing and marketing HIV drugs, including Truvada for pre-exposure prophylaxis (PrEP), its preventive HIV medicine. Along with U.S. trials, Gilead is conducting a randomized, controlled clinical trial in Wuhan, testing remdesivir as a treatment for mild to moderate forms of pneumonia in people with the virus. The trial was given the go-ahead by China’s Food and Drug Administration in February.
YTD Performance: Shares of Gilead are up 13.4%.
- CMC receives 40 vials of remdesivir to treat COVID-19 on May 30, 2020 at 3:45 am
... remdesivir (we received approval through Gilead before GPH was able to ... at the beginning of the pandemic, due to limited supply through Gilead.
- Tag: Gilead Sciences Inc on May 30, 2020 at 2:30 am
Tag: Gilead Sciences Inc. Gilead Study Shows Shorter 5-day Course of Remdesivir Works as Well... Acot-Acot - May 29, 2020. Politics ...
Type: Pandemic adjuvant platform for vaccines
Name: AS03 Adjuvant System
Background: GSK is another leading vaccine maker, having brought to market vaccines for human papillomavirus (HPV) and the seasonal flu, among others. On Feb. 3, it said the CEPI-funded University of Queensland will have access to the British drugmaker’s vaccine adjuvant platform technology, which is believed to both strengthen the response of a vaccine and limit the amount of vaccine needed per dose. On Feb. 24, GSK said that Clover Biopharmaceuticals Inc., a Chinese biotechnology company, is also using its adjuvant technology in combination with its vaccine candidate, Covid-19 S-Trimer, in preclinical studies. Dr. Thomas Breuer, chief medical officer for GSK Vaccines, is leading work on vaccines and the adjuvant platform.
YTD Performance: 23.5%.
- Elderly Nutrition Market with Impact of COVID19 By Top Keyplayers Nestle, Abbott Laboratories ... on May 30, 2020 at 5:57 am
Top Key Players included in this report: Nestle, Abbott Laboratories, Danone, Pfizer, GlaxoSmithKline , ,. The report Elderly Nutrition market present by ...
- Research Report with COVID-19 Forecasts - Global External Nasal Dilator Market 2020-2024 ... on May 30, 2020 at 3:22 am
GlaxoSmithKline Plc operates its business through segments such as Pharmaceuticals, Consumer healthcare, and Vaccines. The company offers ...
Type: Vaccine
Stage: Preclinical
Background: Heat Biologics has previously announced that it is developing a vaccine for the novel coronavirus with the University of Miami Miller School of Medicine. It disclosed March 17 in a financial filing that its Covid-19 vaccine candidate had been added to the World Health Organization’s “draft landscape” of 41 candidate vaccines. The company also recently joined the Alliance for Biosecurity, which may help it “secure government funding to support its rapid development, production, and distribution” of its Covid-19 vaccine, according to Maxim Group analysts.
YTD Performance: 19%.
- Heat Biologics reveals positive patient survival data from its Phase 2 lung cancer trial on May 29, 2020 at 4:38 pm
Heat Biologics, Inc (NASDAQ:HTBX) Chief Scientific and Operating Officer Jeff Hutchins tells Proactive the North Carolina-based biotech presented ...
- BRIEF-Heat Biologics Presents Positive Survival Benefit For Hs-110 In Combination With ... on May 29, 2020 at 2:33 pm
May 29 (Reuters) - Heat Biologics Inc: * HEAT BIOLOGICS PRESENTS POSITIVE SURVIVAL BENEFIT FOR HS-110 IN COMBINATION WITH ...
Type: DNA-based vaccine
Stage: Human Trials
Name: INO-4800
Background: Another CEPI grantee, awarded $9 million, Inovio has said it already began preclinical testing and small-scale manufacturing.
YTD Performance: 124.6%.
- Human Papillomavirus Protein E6 Market with top key players: Rottapharm Biotech Srl,Selecta ... on May 30, 2020 at 4:18 am
... Inc,BioNTech AG,Cancer Research Technology Ltd,Etubics Corp,Genexine Inc,Hookipa Biotech AG,Inovio Pharmaceuticals Inc,MedImmune LLC.
- Huge opportunity in Human Papillomavirus Protein E7 Market 2020-2027 with Abion Inc,Advaxis ... on May 30, 2020 at 3:45 am
... Technology Ltd,Etubics Corp,Formune SL,Genexine Inc,Hookipa Biotech AG,iBio Inc,Immunovaccine Inc,Inovio Pharmaceuticals Inc,MedImmune ...
Type: Vaccine
Name: TBD
Background: On Feb. 11, J&J said it is working with BARDA to test its vaccine candidate, with both organizations providing funding for research and development and the public-health organization funding the Phase 1 trials. Similar to GSK, J&J’s AdVac and PER. C6 technologies are used to improve the development process for a vaccine and were also used to develop J&J’s experimental Ebola vaccine. “We are also in discussions with other partners, that if we have a vaccine candidate with potential, we aim to make it accessible to China and other parts of the world,” Dr. Paul Stoffels, J&J’s chief scientific officer, said in a statement. On March 13, J&J said it started preclinical testing on multiple candidates in collaboration with Beth Israel Deaconess Medical Center in Boston, and it aims to have a vaccine candidate by the end of the month. J&J also said in February that it partnered with BARDA on a project that aims to screen existing antiviral medications, including experimental or approved therapies, that may be effective against Covid-19.
YTD Performance: Down -7.5%.
- What Steps Can We Take as a Society to Prepare Us for Future Pandemics? on May 30, 2020 at 12:40 am
How Johnson & Johnson Helped Unite Nurses For the First-Ever Virtual Nurse ... Are Honoring the Brave Frontline Health Workers Battling COVID-19.
- Quest for COVID-19 vaccines: Where they stand on May 29, 2020 at 11:30 pm
Johnson & Johnson plans to collaborate with Emergent BioSolution to manufacture the vaccine. Sanofi and GlaxoSmithKline. French pharmaceutical ...
Type: RNA-based vaccine
Stage: Human Trials
Name: mRNA-1273
Background: Moderna received funding from CEPI in January to develop an mRNA vaccine against Covid-19. On Feb. 24, it said it had shipped the first batch of mRNA-1273 to the NIAID for a Phase 1 clinical trial in the U.S.
YTD Performance: 51.4%.
- COVID-19: Treatment or vaccines? What seems more likely, and what could be more beneficial? on May 30, 2020 at 5:26 am
Currently, Moderna Inc (NASDAQ:MRNA) is testing its messenger RNA (mRNA) vaccine in a phase I clinical trial in Seattle, Washington. Moderna is ...
- Moderna begins new COVID-19 vaccine study on May 30, 2020 at 2:10 am
Moderna Inc. undefined announced Friday afternoon that the latest study of its ... “2 pm: @NatGeo breaks the news that Moderna's mRNA vaccine has ...
Type: Treatment
Stage: Available
Name: Hydroxychloroquine (HCQ), sold under the brand name Plaquenil
Background: Hydroxychloroquine (HCQ) is a medication used to prevent and treat malaria in areas where malaria remains sensitive to chloroquine.
Mylan NV said Thursday it was restarting production of a medication to treat malaria — hydroxychloroquine sulfate tablets — that could potentially treat Covid-19 if it’s approved by the federal government.
The World Health Organization has listed it as a drug under investigation for treatment against the novel coronavirus, although it isn’t approved for that use in the United States. It is also used to treat rheumatoid arthritis and lupus erythematosus. Mylan said that it restarted production at its Morgantown, West Virginia, plant of the medication and has enough active pharmaceutical ingredient to start supply in mid-April and provide at some point after the ramp-up to 50 million tablets that could treat 1.5 million Covid-19 patients.
YTD Performance: Down −25.75%
- WHO decision to halt trials of hydroxychloroquine is not correct on May 30, 2020 at 2:37 am
WHO decision to halt trials of hydroxychloroquine is not correct: CSIR DG ... Coronavirus outbreak: Indian pharma industry produced 20 crore HCQ ...
- SGPGI, KGMU stick to ICMR advice on HCQ for docs, health staff on May 29, 2020 at 11:15 pm
Lucknow: The World Health Organization (WHO) may have halted the trial of hydroxychloroquine (HCQ) drug due to safety concerns but SGPGIMS ...
Type: vaccines
Phase: preclinical
Background: Novavax, a preclinical biotechnology company, announced Feb. 26 it had several vaccine candidates in preclinical animal studies, and that it plans to initiate a Phase I clinical study by June. In March the company it had received $4 million from CEPI to develop a Covid-19 vaccine and that Emergent BioSolutions Inc. EBS, 10.966% would support contract development and manufacturing for the experimental vaccine.
YTD Performance: 165.6%.
- BRIEF-Novavax Inc Entered Into A Share Purchase Agreement on May 29, 2020 at 10:30 pm
* NOVAVAX INC - ON MAY 27 ENTERED INTO A SHARE PURCHASE AGREEMENT Source text: (bit.ly/2Ajgsas) Further company coverage: Our ...
- BRIEF-Novavax Inc Entered Into A Share Purchase Agreement on May 29, 2020 at 10:30 pm
BRIEF-Novavax Inc Entered Into A Share Purchase Agreement. 1 Min Read. May 29 (Reuters) - Novavax Inc: * NOVAVAX INC - ON MAY 27 ...
Type: Treatment
Stage: Preclinical
Name: No name yet
Background: On Feb. 4, Regeneron announced it is working on developing monoclonal antibodies as treatments for Covid-19. The company’s VelocImmune platform uses genetically-engineered mice with humanized immune systems in preclinical testing. “We are aiming to have hundreds of thousands of prophylactic doses ready for human testing by end of August,” a spokesperson said. Christos Kyratsous, VP of infectious disease R&D and viral vector technology, is running the project.
YTD Performance: 29.8%.
- Human Papillomavirus Protein E6 Market with top key players: Rottapharm Biotech Srl,Selecta ... on May 30, 2020 at 4:18 am
... key players: Rottapharm Biotech Srl,Selecta Biosciences Inc,Transgene SA,Abion Inc,BioNTech AG,Cancer Research Technology Ltd,Etubics Corp.
- Huge opportunity in Human Papillomavirus Protein E7 Market 2020-2027 with Abion Inc,Advaxis ... on May 30, 2020 at 3:45 am
The key manufacturers covered in this report are: Abion Inc,Advaxis Inc,Bioleaders Corp,BioNTech AG,Cancer Research Technology Ltd,Etubics Corp, ...
Type: Vaccine
Stage: Preclinical
Name: No name yet
Background: Starting Feb. 18, Sanofi is working with BARDA to test a preclinical vaccine candidate for severe acute respiratory syndrome (SARS) for Covid-19 using its recombinant DNA platform. It has a long history of producing vaccines in its Sanofi Pasteur business and acquired this candidate through its 2017 acquisition of Protein Sciences for $750 million. The French drugmaker previously worked with the organization on flu vaccines. Scientists in Meriden, Ct., are working on the vaccine; David Loew, Sanofi Pasteur’s EVP, is leading the project.
YTD Performance: 14.4%.
- COVID – 19 Impact On Global Atopic Dermatitis Treatment Market 2020 Analysis By Top Players ... on May 30, 2020 at 5:26 am
Some of the market players that are included are Sanofi, RegeneronPharmaceuticals, AstellasPharma, AnacorPharmaceuticals, MedaAB, ...
- Recent Analysis of Pediatric Vaccine Market | • Seqirus • GlaxoSmithKline • Sanofi Pasteur • Daiichi ... on May 29, 2020 at 9:45 pm
Sanofi Pasteur • Daiichi Sankyo • Panacea Biotec. Post author By harsha ...
Type: Treatment
Stage: Preclinical
Name: TAK-888
Background: The Japanese drugmaker said March 4 it plans to test hyperimmune globulins for people who are at high risk for infection. As part of its research, which will be performed in Georgia, Takeda said it would need access to plasma from people who have recovered from Covid-19 or those who have received a vaccine if one is developed. Dr. Rajeev Venkayya, president of Takeda’s vaccine business, is the co-lead of the company’s Covid-19 response team. Like J&J, Takeda plans to examine whether other therapies, both experimental or with regulatory approval, may have treatment potential.
YTD Performance: 29.0%.
- Gastrointestinal Disorder Therapeutics Market Growth, Overview with Detailed Analysis 2020-2026 ... on May 30, 2020 at 3:45 am
Top Key Players @ AstraZeneca,Takeda Pharmaceutical,Johnson ... Pharma. Sample Copy of Gastrointestinal Disorder Therapeutics Market Report ...
- Other news to note for May 29, 2020 on May 29, 2020 at 10:51 pm
Sumitomo Dainippon Pharma Co. ... Takeda Pharmaceutical Co. ... SHP-647 and certain associated rights, a commitment Takeda provided to secure ...
Type: Vaccine
Stage: Preclinical
Background:Vaxart was one of the first companies to announce plans to develop a vaccine when it did so Jan. 31. In March the clinical-stage company announced that Emergent BioSolutions will help develop and manufacture its oral vaccine candidate. “We believe an oral vaccine administered using a room temperature-stable tablet may offer enormous logistical advantages in the roll-out of a large vaccination campaign,” Vaxart CEO Wouter Latour said in a March 18 news release. The company plans to start a Phase 1 clinical trial in the U.S. in the second half of 2020, a company executive said.
YTD Performance: 516.3%.
- Vaxart Inc. [VXRT] moved up 0.76: Why It's Important on May 29, 2020 at 3:00 pm
Vaxart Inc. [NASDAQ: VXRT] surged by $0.02 during the normal trading session on Thursday and reaching a high of $2.70 during the day while it ...
- An Unsustainable Story, The Stocks Should Be Avoided? Enservco Corporation (ENSV) and ... on May 29, 2020 at 2:12 pm
Enservco Corporation (ENSV) and Vaxart Inc. (VXRT). By. Melanie Gerald. -. May 29, 2020.
Bitcoin
Ethereum
Xrp
Bitcoin cash
Litecoin
Eos
Tezos
Dash
Stellar
Ethereum classic
Zcash
Thank you for your Bitcoin donation
Scan the QR code or copy the address below into your wallet to send Bitcoin
Thank you for your Ethereum donation
Scan the QR code or copy the address below into your wallet to send Ethereum
Thank you for your Xrp donation
Scan the QR code or copy the address below into your wallet to send Xrp
Thank you for your Bitcoin cash donation
Scan the QR code or copy the address below into your wallet to send Bitcoin cash
Thank you for your Litecoin donation
Scan the QR code or copy the address below into your wallet to send Litecoin
Thank you for your Eos donation
Scan the QR code or copy the address below into your wallet to send Eos
Thank you for your Tezos donation
Scan the QR code or copy the address below into your wallet to send Tezos
Thank you for your Dash donation
Scan the QR code or copy the address below into your wallet to send Dash
)
Thank you for your Stellar donation
Scan the QR code or copy the address below into your wallet to send Stellar
Thank you for your Ethereum classic donation
Scan the QR code or copy the address below into your wallet to send Ethereum classic
Thank you for your Zcash donation
Scan the QR code or copy the address below into your wallet to send Zcash
